Trinity Biotech PLC (TRB.BE)
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable ...
Model output · Signal date 2026-10-16
Trinity Biotech Plc (TRIB) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Rating · 90D
Total
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Middle 30%
of 5172 stocks scored
Rank correlation · 90D
-5.0%
Spearman, 357 dates
Market Cap
$7M
small-cap · #14 of 17 peers
Summary
Trinity Biotech Plc (TRIB) stock forecast summary
On Oct. 16, 2026, TRIB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Trinity Biotech Plc is a small-cap company with a market capitalization of $7M. It ranks number 14 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.
For TRIB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -5.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TRIB included.
Follow TRIB freePrice
TRIB price chart and AI forecast
Cross-section · 2026-10-16
How TRIB ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2022-04-30
Trinity Biotech Plc (TRIB) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | TRIB | Rank |
|---|---|---|
| Market Cap | $7M | 14/17 |
Dividend & Shareholder Information
| Metric | TRIB | Rank |
|---|---|---|
| Shares Outstanding | 1M | – |
Balance Sheet Highlights (USD millions)
| Total Liabilities | $128M |
Quarterly Financial Reports
TRIB quarterly financials and insider trading
Industry Peers · In Vitro & In Vivo Diagnostic Substances
Trinity Biotech Plc (TRIB) industry peers
Companies classified under the same SEC industry code as Trinity Biotech Plc (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| TRIB Trinity Biotech Plc | ▶ | $7M |
| IDXX Idexx Laboratories Inc /De | ▼ | $44.15B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.51B |
| NEOG Neogen Corp | ▲ | $2.58B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.16B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.60B |
| QDEL Quidelortho Corp | ▲ | $885M |
| ACHV Achieve Life Sciences, Inc. | ▲ | $657M |
| MYGN Myriad Genetics Inc | ▲ | $381M |
| TKNO Alpha Teknova, Inc. | ▲ | $380M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▼ | $98M |
| AWHL Aspira Women's Health Inc. | ▲ | $11M |
| BMRA Biomerica Inc | ▲ | $9M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▲ | $5M |
| QCLS Q/C Technologies, Inc. | ▼ | $4M |
| VNRX Volitionrx Ltd | ▶ | $2M |
Where TRIB sits on the market map
Life Sciences · In Vitro & In Vivo Diagnostic Substances
News
Trinity Biotech Plc (TRIB) stock news
Trinity Biotech plc Receives Nasdaq Compliance Notice Regarding Bid Price and Market Value Requirements
Trinity Biotech received Nasdaq notices for non-compliance with bid price and market value requirements, with 180 days to address deficiencies. Trinity Biotech plc, a biotechnology company ...
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions ...
FAQ
Trinity Biotech Plc (TRIB) stock forecast FAQ
What is the Trinity Biotech Plc (TRIB) stock forecast?
On Oct. 16, 2026, TRIB is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Trinity Biotech Plc stock predictions?
For TRIB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -5.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Trinity Biotech Plc forecasts updated?
Trinity Biotech Plc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Trinity Biotech Plc's industry peers?
17 issuers in our coverage, TRIB included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.